BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
search help

Documents 1-17 out of 17 found
  Current Search:  rau: 514, sed: 5370, reserpine: 122  

100%
TEXT
http://www.fda.gov/cder/orange/appendix_a.txt
4, ACETAMINOPHEN PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN PHENAZINE, PHENDIMETRAZINE TARTRATE PHENAZINE-35, PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE PHENERGAN W/ CODEINE, CODEINE...

Matching: rau sed reserpine Find similar documents More document info
100%
TEXT
WAIS Document Retrieval
[Federal Register: October 8, 1998 (Volume 63, Number 195)] [Proposed Rules] [Page 54082-54089] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr08oc98-22] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug...

Matching: rau sed reserpine Find similar documents More document info
100%
PDF
Document
54082 Federal Register / Vol
The primary focus of this proposed rule is drug products that have been removed or withdrawn for safety reasons
Duract capsules were voluntarily withdrawn from the market by their manufacturer on June 22, 1998
FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...

author: U.S. Government Printing Office subject: Extracted Pages
Matching: rau sed reserpine Find similar documents More document info

100%
PDF
Document page 5


author: U.S. Government Printing Office subject: Extracted Pages
duplicates:
http://www.fda.gov/cder/fdama/10898.pdf
Matching: Find similar documents More document info

100%
PDF
Document
54082 Federal Register / Vol
The primary focus of this proposed rule is drug products that have been removed or withdrawn for safety reasons
Duract capsules were voluntarily withdrawn from the market by their manufacturer on June 22, 1998
FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...

author: U.S. Government Printing Office subject: Extracted Pages
Matching: rau sed reserpine Find similar documents More document info

65%
HTML
Aging and Drugs: Merck Manual Home Edition
Section Drugs Subject Aging and Drugs Aging and Drugs Older people tend to take more drugs than younger people because they are more likely to have several, often chronic disorders.
Also, other, safer drugs can often be substituted.
Not following a doctor's directions for taking a drug (noncompliance or nonadherence) can be risky (see Compliance With Drug Treatment:...
Matching: sed reserpine Find similar documents More document info
65%
HTML
Aging and Drugs: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
Matching: sed reserpine Find similar documents More document info
65%
HTML
Index: RE: Merck Manual Home Edition
Pain: Pain Pathways Low Back Pain: Causes Low Back Pain: Symptoms and Types of Low Back Pain Reflex epilepsy Seizure Disorders: Causes Reflexes Reflex Arc: A No-Brainer DIAGNOSTIC PROCEDURES acoustic Ears: Middle Ear diving Near Drowning knee jerk Reflex Arc: A No-Brainer Accident-Related Injuries let-down Home (What to Expect) Feeding: Breastfeeding in newborn Physical Examination...
Matching: sed reserpine Find similar documents More document info
65%
PDF
Specificity Table TOX.xls
Tested (ng/ ml) Redeptin Fluspirilene Neuroleptic 100,000 Reglan Metoclopramide Peristaltic stimulant 1,000,000 Regletin Alprenolol Antiarrhythmic 200,000 Reglone Diquat Herbicide 10,000 Relafen Nabumetone Anti- inflammatory 100,000 Remeron Mirtazepine Antipsychotic 1,000,000 Reserpex Reserpine Antihypertensive 100,000 Restoril Temazepam Benzodiazepine 100,000 BZO 200 Restoril...

author: Biosite Incorporated
Matching: sed reserpine Find similar documents More document info

65%
HTML
Cancer.gov - Depression (PDQ®)
Depression (PDQ®) Two versions of this document are available
Reserpine
Although most patients will develop tolerance to antidepressants' sedative effects with continued treatment, the need for soporific agents may diminish with improvement in depressive symptoms
Analeptics are sometimes used adjuvantly to antagonize opioid analgesics' sedative effects...
Matching: sed reserpine Find similar documents More document info
65%
HTML
LIST OF APPROVED DRUGS FOR WHICH ADDITIONAL PEDIATRIC INFORMATION
DOCKET NO
Anesthetic, Critical Care And Addiction Drug Products Bupropion Treatment of depression
Metabolic And Endocrine Drug Products Dexmedetomidine Sedation of initially intubated and mechanically ventilated patients in an ICU setting
Prolonging the time to recurrence of supraventricular tachycardia
Special Pathogen And Immunologic Drug Products Flumazenil Complete or...
Matching: sed reserpine Find similar documents More document info
65%
HTML
Pharmacy 370
- - COURSE & NUMBER: PHARMACY 370 COURSE TITLE: MEDICINAL CHEMISTRY REQUIRED: Yes YEAR: Second TERM: Both First and Second HOURS PER WEEK: LECTURE ----- 3 SEMINAR ----- 0 COMPUTER LABORATORY – Available ...
Matching: sed reserpine Find similar documents More document info
65%
PDF
may20lst.PDF
98N- 0056 May 20, 1998 Page 6 Drug Name Potential pediatric use limited to approved indications Age Group In Which More Information Needed birth to 1 mos 1 mos to 2 yrs 2 to 12 years 12 to 16 years Milrinone Treatment of heart failure Yes Yes Yes Yes Minoxidil Hypertension Yes Yes Yes Yes Moexipril Hypertension Yes Yes Yes Yes Moexipril/ Hydrochlorothiazide Hypertension Yes Yes Yes...

author: Unknown
Matching: sed reserpine Find similar documents More document info

65%
PDF
http://www.emea.eu.int/pdfs/vet/mrls/romifidine.pdf
The European Agency for the Evaluation of Medicinal Products 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel: (+ 44- 171) 418 84 00 Fax: (+ 44- 171) 418 84 16 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ROMIFIDINE SUMMARY REPORT SAFETY FILE 1. Romifidine is a member of the chemical class of ...

author: Jerry Wells
Matching: sed reserpine Find similar documents More document info

65%
PDF
http://www.emea.eu.int/pdfs/vet/mrls/romifidine.pdf page 3
Rabbits appeared less susceptible and no effects in dams and their offspring were observed at oral doses of 0.15 and 0.4 mg/ kg bw. It was concluded that Romifidine induced embryotoxic effects occur only at oral doses higher than 0.15 mg/ kg bw in rats and at oral doses higher than 1 mg/ kg bw in rabbits. ...

author: Jerry Wells
Matching: sed reserpine Find similar documents More document info

60%
PDF
issue18
Monterotondo celebrates mouse house ..
Centres w ll also fac l tate the development of methods and rap d technology exchange across the Laboratory
Lab Day w ll take place on June 15- 16, 2004, at the ma n Laboratory n He delberg
He surpr sed l steners w th the f nd ng that glutamate acts ntracellularly n sweat glands, thereby modulat ng the chlor de conductance to b...

author: Sherwood
Matching: rau sed Find similar documents More document info

60%
HTML
Max Planck Society - Max Planck Research Reports (ongoing)
- HOME Contact Newsroom Links Site-Map Disclaimer FAQs Deutsch - Quickfinder Events Calendar Help guests scientists Institutes Job Opportunities Junior Research Group President Presidential Commiss
Authors: Wunderer CB
Andritschke R
pnCCDs on XMM-Newton - 42 months in orbit Source: [Article] Nuclear Instruments & Methods in Physics Research Section A-Accelerators...
author: Max Planck Gesellschaft e.V
Matching: rau sed Find similar documents More document info

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.